CoDiagnostics Advances Global Health Commitment with TB Diagnostics Course Participation

CoDiagnostics Strengthens Commitment to Global Health Through Advanced TB Diagnostics Course Participation

CoDiagnostics, Inc., a molecular diagnostics leader based in Utah, announces its joint venture, CoSara Diagnostics Pvt. Ltd., will actively participate in the 2nd Advanced TB Diagnostics Course scheduled for December 15-19, 2025. This event, hosted by the ICMR–National Institute for Research in Tuberculosis (NIRT) in Chennai, India, aims to address critical challenges in tuberculosis (TB) detection and research across the South-East Asian Region (SEAR). The course is a collaborative effort involving the ICMR-NIRT, the McGill International TB Centre, and various global health organizations, reaffirming CoDiagnostics' role in the fight against infectious diseases.

The Advanced TB Diagnostics Course is designed to enhance the capabilities and knowledge of participants in the field of tuberculosis diagnostics. It includes a comprehensive agenda that covers the entire diagnostics value chain, from the introduction of innovative technologies to cost-effectiveness modeling and the development of evidence-based policies. Key presentations and discussions are set to feature leading experts from prestigious organizations such as the World Health Organization (WHO), The Gates Foundation, and Boston University. This gathering represents a significant opportunity for CoSara and CoDiagnostics to showcase their advanced diagnostic solutions and contribute to closing the TB case-finding gap—a critical public health issue in the region.

CoDiagnostics is dedicated to developing and manufacturing advanced diagnostic technologies, utilizing its proprietary platform for nucleic acid detection and analysis. The company is also in the process of advancing its Co-Dx PCR at-home and point-of-care platform, which aims to detect genetic markers for a variety of health conditions. While this platform is currently under regulatory review and not yet available for commercial use, the participation in the TB diagnostics course highlights CoDiagnostics' commitment to enhancing global health initiatives. By engaging with experts and sharing knowledge, the company is poised to play a pivotal role in addressing significant public health challenges like tuberculosis.

In addition to its participation in the Advanced TB Diagnostics Course, CoDiagnostics continues to innovate in the field of molecular diagnostics. The company's focus on developing advanced testing solutions underlines its mission to improve healthcare outcomes worldwide. As the global health landscape evolves, CoDiagnostics remains at the forefront, addressing urgent needs in infectious disease detection and paving the way for future advancements in diagnostics.